Department of Otolaryngology-Head and Neck Surgery, Counties Manukau District Health Board, Auckland, New Zealand.
Middlemore Clinical Trials, Auckland, New Zealand.
Laryngoscope. 2021 May;131(5):E1503-E1509. doi: 10.1002/lary.29111. Epub 2020 Sep 29.
This study aims to review the effects of short- and long-term oral administration of postoperative corticosteroids in patients undergoing sialendoscopy for the treatment of obstructive sialadenitis due to ductal stenosis.
Prospective comparative study.
A prospective observational study was conducted at Manukau Surgical Center in Auckland, New Zealand, where patients undergoing sialendoscopic surgery for recurrent obstructive sialadenitis due to ductal stenoses were reviewed. Univariable and multivariable analysis, and also logistic regression were performed to identify variables correlated with the likelihood of the need for revision surgery for persistent or recurrent symptoms.
In this study, sialendoscopy was performed in 142 patients: 162 parotid glands (86.6%) and 25 submandibular glands (13.4%). Postoperative oral steroids were prescribed for 48 patients (34%); 19 (13%) were prescribed for less than 7 days and 29 (20%) for more than 7 days. In total, 33 patients (23.2%) required a revision sialendoscopy during follow-up due to recurrence of symptoms. Oral steroids prescribed for more than 7 days after a sialendoscopy reduced the likelihood of a revision procedure by 93% when compared with patients who did not receive this medication, and by 96% when compared with patients who received steroids for less than 7 days.
The results showed that in our population oral administration of corticosteroids for more than 7 days after sialendoscopy for the treatment of recurrent obstructive sialadenitis due to ductal stenosis markedly reduced the need for later revision surgery. Routine use of corticosteroids for more than 7 days is recommended after sialendoscopy in patients with ductal stenosis.
II Laryngoscope, 131:E1503-E1509, 2021.
本研究旨在回顾因导管狭窄导致阻塞性唾液腺炎而行涎腺镜治疗的患者短期和长期口服皮质类固醇的效果。
前瞻性对照研究。
在新西兰奥克兰的 Manukau 外科中心进行了一项前瞻性观察性研究，对因导管狭窄导致复发性阻塞性唾液腺炎而行涎腺镜手术的患者进行了回顾性分析。采用单变量和多变量分析以及逻辑回归分析，以确定与持续性或复发性症状需要再次手术相关的变量。
本研究中，对 142 例患者（162 例腮腺和 25 例下颌下腺）进行了涎腺镜检查。48 例（34%）患者术后给予口服皮质类固醇；19 例（13%）患者服用时间少于 7 天，29 例（20%）患者服用时间超过 7 天。在随访期间，共有 33 例（23.2%）患者因症状复发需要再次涎腺镜检查。与未接受该药物治疗的患者相比，接受 7 天以上皮质类固醇治疗的患者再次手术的可能性降低了 93%；与接受皮质类固醇治疗少于 7 天的患者相比，再次手术的可能性降低了 96%。
结果表明，在我们的人群中，因导管狭窄导致的复发性阻塞性唾液腺炎而行涎腺镜治疗后，口服皮质类固醇超过 7 天可显著减少再次手术的需要。建议对有导管狭窄的患者在涎腺镜术后常规使用皮质类固醇超过 7 天。
Ⅱ级 Laryngoscope, 131:E1503-E1509, 2021.
